Peptides Save Lives

The Body's Intelligent Messengers

Dispatch: Suppressed Science, Peptides, Health Sovereignty, Precision Medicine, Kidney Disease, Alzheimer’s, Cancer, Heart Disease

---

If you are living with a chronic disease that mainstream medicine told you has no viable options left, if you are feeling hopeless, then this information is absolutely worth knowing about.

In 2016, I had an operation to remove eight large tumours with my womb, that had been crushing my kidneys and organs for three years. Little did I know that this had caused me acute kidney injury and a decade later I am living with Stage 4 chronic kidney disease. As someone who has lived with serious health issues since I was very young, such as tumours that my doctors told me will likely grow back in different places yet are termed as a medical anomoly as they are benign. This forced me into a much deep dive into research without settling for ‘irreversible’’, or ‘no other viable options available’. I needed to find knowledge that existed outside of what was offered in the usual mainstream, that focused only on managing the slow decline, inevitable dialysis, agonizing wait for a transplant and life long medication of immune suppressants and anti-rejection therapy. What I found buried deep within peer-reviewed journals, at private research clinics and at university research departments, with actual Phase 2 and Phase 3 clinical trials, was something far more hopeful. It isn’t ‘alternative medicine.’ It is rigorous science, pioneering treatments that produced real results in conditions mainstream approaches simply hadn’t solved yet.

This emerging field is called peptide therapy. And frankly, the amount of research being done around this right now is one of the most significant and yet least reported stories happening in modern medicine, its not something you will hear about in mainstream media, not yet anyway.

What Exactly Is a Peptide?

Think about amino acids are like the alphabet, proteins are the finished information manual. Peptides are the sentences, the critical, information-rich molecules built anywhere from two to fifty amino acids. The human body uses these intelligent messengers all the time, relaying specific instructions from one cell to another.

For example: insulin is a peptide. Oxytocin, that amazing bonding hormone you feel when you hug someone you care about, is also a peptide. At its most basic level, the body’s communication system is this endless conversation, and peptides are simply the language used for that exchange.

Why does this matter so much? Because these therapeutic peptides can offer precision treatment while keeping their toxicity load low. They use building blocks that the human body already knows and understands. The biggest hurdle we faced historically was always delivery, because they’re incredibly fragile peptides would just get destroyed in the bloodstream before they would ever reach their destination. Thankfully, nanotechnology is solving this problem now, and we are starting to see truly revolutionary effects across several major disease areas at once, this is where it gets really interesting.

Mitochondria are the common thread of illness, it is necessary to understand this first of all because it runs through almost every single piece of exciting research I’m about to share. Inside nearly every cell in your body are these mitochondria. They are these tiny powerhouses responsible for converting oxygen and nutrients into usable energy. Honestly, understanding them is the key component to health and healing, but we still have not fully grasped it. Your heart, kidneys, and brain are some of the biggest energy consumers, it is where most mitochondria are concentrated, and these organs are the most impacted when their internal mitochondria start malfunctioning.

The a staggering truth is nearly every chronic condition we know, heart failure, kidney failure, cancer, or Alzheimer’s, and even Long COVID, shares mitochondrial dysfunction as one of its primary root causes. So if we can find a way to prevent mitochondrial collapse, then we can address the root cause of all fatal illness.

A compound called cardiolipin, a unique phospholipid found right inside the mitochondria, is a crucial component of that entire energy-generating machine, It plays a critical role in energetic metabolism . But when these diseases hit, it gets damaged. This damage doesn’t just mean lower energy; it triggers massive inflammation, scarring, and eventually, organ failure.

The most promising peptide discovered for targeting this specific issue is elamipretide (also known as SS-31). It was intentionally designed to bind directly to cardiolipin to stabilize mitochondrial function, supporting the cell’s entire energy system and helping restore function from the inside out. Because it addresses mitochondrial dysfunction right at the source, its relevance spans practically everything we’re about to talk about.

Kidney Disease- where irreversible is no longer the last diagnosis.

Eight hundred fifty million people worldwide live with kidney disease and many millions more are walking around unaware they have stage two or stage three kidney disease. The conventional narrative is brutal, progressive, and deeply pessimistic. You are told your options are limited to dialysis or waiting for a transplant that might never materialize along with life long medication in the form of immune suppressants and anti-rejection medication. Critically, none of those narratives even manage to explain why the kidneys are actually failing in the first place. Yet, over the last twelve months there have been some significant changes which should be all over the mainstreamt news, but you won’t have heard anything about probably because the organ donation industry is one that makes a significant figure worth over $1 billion per year.

A major review came out last June 2025, published by researchers from the European Wellness Group and UC Irvine. They present two peptide platforms that genuinely tackle the root cause of kidney failure. The first is nano-organo peptides (NOPs), these aren’t just general drugs; they are designed to deliver active peptides with pinpoint precision directly into diseased kidney tissue, even reaching those tough spots of hardening, scarring or inflammation where traditional medicine simply cannot get through. The second peptide platform involves elamipretide, which goes straight to the struggling mitochondria within the kidney cells to restore function at its core.

In animal models, elamipretide showed amazing results, protecting kidney cells, drastically reducing cell death, and restoring full function in a single day. Then came the Phase 2a human trial, where it successfully lowered inflammation and improved function after just three months for patients with kidney artery stenosis. Of course further larger trials are to be carried out to confirm everything, but this progress is profoundly encouraging, having a significant impact on lives already, (see the video below) and for people like me, who feel they have run out of all other options, this means absolutely everything.

The Heart, Restoring What Conventional Medicine Cannot

Heart failure affects sixty-four million people globally, and the five-year mortality rate is higher than most cancers. The main problem at its foundation is the failing mitochondria right inside the heart muscle itself. Until recently, conventional drugs just couldn’t address this core energy problem directly.

In studies with dogs suffering from advanced heart failure, just three months of daily elamipretide significantly boosted the ejection fraction, the key measure of how powerfully the heart pumps, along with cardiac output and overall relaxation. Another interesting case study is a human trial (TAZPOWER) for Barth syndrome, a rare disorder where the heart simply doesn’t generate enough energy to function. The peptide Elamipretide has been showin to dramatically improved heart strength, reduced fatigue, and maintained those benefits for over 168 weeks, that is by far the longest documented clinical benefit ever seen for any mitochondria-targeted peptide in cardiology.

Even more striking, is a study from Harvard Medical School in 2025 showed that just eight weeks of elamipretide partially reversed age-related heart decline in older mice, and they didn’t even change their underlying epigenetic age markers. This points to something massive, that the peptide seems capable of helping specific tissues recover from mitochondrial damage, rather than simply trying to trick or bypass the aging process altogether.

Cancer-Precision healing

Conventional chemotherapy is not selective, it loads the entire body with toxins, It distinguish where it is going. It will affect the gut lining, bone marrow, your hair follicles, and even your immune system, which all take a massive hit right alongside the tumour. This is a great cost which patients are affected by for the rest of their recovery and this carries significant impact on their health. Peptide-drug conjugates address this issue fundamentally. They use a “homing” peptide, a kind of natural GPS beacon, that actively seeks out only the malignant cells, delivering their toxic payload precisely at the target site. Healthy tissue is completely untouched.

The TP53 gene, located on chromosome 17, encodes the p53 protein, a critical tumor suppressor protein, known as a guardian that triggers apoptosis in damaged or cancerous cells. Many peptide cancer therapies work intelligently by reactivating or mimicking p53 function, or by targeting the same apoptosis pathways that p53 controls. The glucose inhibition mechanism also has a peptide parallel. Several peptide-drug conjugates and mitochondria-targeted peptides work partly by disrupting cancer cell energy metabolism.

The FDA has already approved proof of concept for this technology. For example, Lutathera targets neuroendocrine tumours with a radioactive dose, making considerable survival improvements in Phase 3 trials. Similarly, Sacituzumab govitecan showed better outcomes for patients with treatment-resistant triple-negative breast cancer, for whom all other lines of treatment had already failed.

In 2024 emerged a huge development of CBX-12, it’s a new drug that targets tumour cells without needing to find standard surface receptors. After strong early studies, the FDA approved its application. Phase 1 trials finished enrolling patients in September 2024, with Phase 2 starting right after positive initial signals were found in platinum-resistant ovarian cancer. Right now, about ninety-six peptide-drug conjugates are being developed across the field, and six are already in Phase 3 trials. The peptide field of research may become a new option of therapy to explore for cancer patients.

Alzheimer’s Disease

For decades, treating Alzheimer’s meant managing symptoms; it never touched the underlying biology itself. That era of care is officially over.

The FDA approved two anti-amyloid therapies, lecanemab and donanemab, making them the first truly disease-modifying treatments for Alzheimer’s in over twenty years. Donanemab, in one of the largest studies ever conducted, demonstrated a statistically significant slowing of cognitive decline and measurable reduction of amyloid plaques, with the strongest results being seen in early-stage patients.

The next massive frontier is tackling Tau protein. BIIB080 showed reduced tau accumulation on PET imaging compared to placebo, accompanied by favuorable cognitive trends. The FDA fast-tracked it in April 2025. A paper published last December 2025 in Cell even called this evidence a biological modification of the pathology itself.

Long COVID & Vaccine Injury-

This is where the need feels the most urgent, and consequently, the available evidence remains the most frustratingly limited due to ongoing censorship despite the overwhelming numbers of vaccine injured patients, so I want to be extremely careful with my words here.

Long COVID and post-vaccine syndrome are a messy mix of ongoing fatigue, brain fog, immune issues, heart problems, and mitochondrial dysfunction. Conventional medicine has not established definitive treatments for these complex issues. In 2025, the NIH’s RECOVER program selected its initial treatment groups with $1.15 billion in funding. Peptides were excluded from this round, simply because we don’t yet have completed randomized controlled trials specific to this overwhelmingly large global population.

But what does exist is a compelling biological Peptide, Thymosin alpha-1 which calms the immune system down without actually suppressing it, making it theoretically perfect for the chronic immune mess seen in Long COVID. In severe COVID-19 patients, studies showed improved immune recovery and reduced mortality. BPC-157 has thirty-six preclinical studies documenting healing effects across the gut, brain, heart, and connective tissue, all highly relevant to the multi-system failure of Long COVID, though large scale human trials are still waiting in line. Finally, elamipretide’s application to post-exertional energy failure is scientifically sound, with clinical trials for this group awaiting completion.

The underlying biology here is profoundly promising; we just need the time and resources to catch up on the clinical evidence. For people living with conditions that medicine hasn’t figured out how to treat yet, that gap doesn’t just affect your daily routine, it affects your quality of life.

What This Means

Peptide therapeutics are not a magic cure-all. The field is brand new, we know that some peptides which looked brilliant in animal models, unfortunately failed miserably in during human trials. The biggest challenge is also manufacturing these molecules, its incredibly complex, expensive and the leading researchers openly discuss all of this complexity in their journals.

But fundamentally, what we are seeing is a real, documented, peer-reviewed field showing results where conventional drugs simply could not reach. It operates by mechanisms that align perfectly with our newest understanding of chronic illness at the molecular level, and most importantly, it utilizes the body’s own systems to heal.

The human body has an intelligence, those repair molecules are innate. Sometimes these systems get disrupted by illness, but they can be profoundly supported by intelligent messengers such as peptides that carry the instruction code to speak to the mitochondria or the affected area of the body.

by

Carlita Shaw

Carlita Shaw is an environmental science writer, author, conservationist, and consciousness researcher with over two decades of work in tropical conservation and ecological science. Her previous articles on plant and animal consciousness, are available in the newsletter archive. Her books include The Silent Ecocide Redux, Surviving Depression in a Depressing World, and the forthcoming Multidimensional Nature.

References

Chan MKS, Wong MBF, Casazza K, Lakey JRT. (2025). Emerging Peptide Therapies for Kidney Disease: Focus on Nano-Organo and Mitochondria-Targeted Strategies. American Journal of Biomedical Science and Research, 27(3). https://biomedgrid.com/pdf/AJBSR.MS.ID.003551.pdf

Mitchell W et al. (2025). The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging. Aging Cell. https://doi.org/10.1111/acel.70026

Thompson WR et al. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine, 26(7), 101138.

Tung C et al. (2025). Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International Journal of Molecular Sciences, 26(3), 944.

Sabbah HN et al. (2016). Chronic Therapy With Elamipretide (MTP-131) Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circulation: Heart Failure, 9, e002206.

Rehman HM et al. (2025). Unlocking the potential of tumor-targeting peptides in precision oncology. Oncology Research, 33(7), 1547–1570.

Armstrong et al. (2025). Peptide-Drug Conjugates: A New Hope for Cancer. Journal of Peptide Science. https://doi.org/10.1002/psc.70040

Al Khzem AH, Gomaa MS. (2026). Peptide-Based Therapeutics for Alzheimer’s Disease. Drug Design, Development and Therapy. Dove Medical Press.

Cell Editorial. (2025). The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau. Cell. https://doi.org/10.1016/S0092-8674(25)01368-6

Miyamoto S et al. (2020). Restorng mitochondrial superoxide levels with elamipretide protects db/db mice against progression of diabetic kidney disease. Journal of Biological Chemistry, 295(21), 7249–7260.

European Wellness Biomedical Group. (2025). Rebuilding the Barrier: Peptide-Based Strategies for Intestinal Regeneration. American Journal of Biomedical Science and Research. https://european-wellness.eu/publications/rebuilding-the-barrier/

Fontecha-Barriuso M et al. (2022). Tubular Mitochondrial Dysfunction, Oxidative Stress, and Progression of Chronic Kidney Disease. Antioxidants, 11(7), 1356.